Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Signe Lykke Nielsen"'
Autor:
Eva Budinska, Nils Brünner, Mauro Delorenzi, Arnaud Roth, Sabine Tejpar, Fred Bosman, Signe Lykke Nielsen, Ben Vainer, Sune Boris Nygård
Supplementary Table S1: Baseline characteristics of biomarker stage III vs PETACC3 stage III. Supplementary Table S2: Baseline characteristics of biomarker stage II + III vs PETACC3 stage II + III. Supplementary Table S3: Treatment effects in the bio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34b83afb2ddc2723c5c6843380d82f41
https://doi.org/10.1158/1078-0432.22458354
https://doi.org/10.1158/1078-0432.22458354
Autor:
Eva Budinska, Nils Brünner, Mauro Delorenzi, Arnaud Roth, Sabine Tejpar, Fred Bosman, Signe Lykke Nielsen, Ben Vainer, Sune Boris Nygård
Purpose: Prospective–retrospective assessment of the TOP1 gene copy number and TOP1 mRNA expression as predictive biomarkers for adjuvant irinotecan in stage II/III colon cancer.Experimental Design: Formalin-fixed, paraffin-embedded tissue microarr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53ccf3682c159f9c0cb28699ca84c283
https://doi.org/10.1158/1078-0432.c.6523920
https://doi.org/10.1158/1078-0432.c.6523920
Autor:
Camilla Qvortrup, Line Schmidt Tarpgaard, Per Pfeiffer, Nils Brünner, Sönke Detlefsen, Signe Lykke Nielsen, Jan Stenvang
Publikováno v:
Tarpgaard, L S, Qvortrup, C, Nielsen, S L, Stenvang, J, Detlefsen, S, Brünner, N & Pfeiffer, P 2021, ' New use for old drugs : Epirubicin in colorectal cancer ', Acta Oncologica, vol. 60, no. 7, pp. 954-956 . https://doi.org/10.1080/0284186X.2021.1904519
We have previously published an article describing the protocol for a clinical, non-randomized phase II study (Eudract no. 2013-001648-79) [1], which aimed to provide proof of concept for introduci...
Autor:
Tim Svenstrup Poulsen, Maria Unni Rømer, Nils Brünner, Iben Kümler, Jan Stenvang, Signe Lykke Nielsen, Dorte Nielsen, Estrid Høgdall, Eva Balslev, José M.A. Moreira, Sune Boris Nygård, Ib Jarle Christensen
Publikováno v:
International Journal of Cancer. 137:2000-2006
Topoisomerase-1 (Top1) targeting drugs have shown promising efficacy in patients with metastatic breast cancer (BC). However, these drugs are rather toxic calling for development and validation of predictive biomarkers to increase the therapeutic ind
Autor:
Iben Kümler, Sofie S. Jespersen, Nils Brünner, Ann S. Knop, Signe Lykke Nielsen, Dorte Nielsen, Tobias Wirenfeldt Klausen, Eva Balslev
Publikováno v:
Applied immunohistochemistrymolecular morphology : AIMM. 26(1)
Tumor heterogeneity has been shown for several cancers including breast cancer (BC). Despite the fact that expression of tumor markers may change throughout the metastatic process, rebiopsies at the time of recurrence are still not performed routinel
Autor:
Sune Boris Nygård, Sönke Detlefsen, Diana R. Andersen, Per Pfeiffer, Camilla Qvortrup, Signe Lykke Nielsen, Line Schmidt Tarpgaard, Nils Brünner, Jan Stenvang, Niels Frank Jensen
Publikováno v:
BMC Cancer
Tarpgaard, L S, Qvortrup, C, Nygård, S B, Nielsen, S L, Andersen, D R, Jensen, N F, Stenvang, J, Detlefsen, S, Brünner, N & Pfeiffer, P 2016, ' A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification ', BMC Cancer, vol. 16, 91 . https://doi.org/10.1186/s12885-016-2124-5
Tarpgaard, L S, Qvortrup, C, Nygård, S B, Nielsen, S L, Andersen, D R, Jensen, N F, Stenvang, J, Detlefsen, S, Brünner, N & Pfeiffer, P 2016, ' A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification ', B M C Cancer, vol. 16, 91 . https://doi.org/10.1186/s12885-016-2124-5
Tarpgaard, L S, Qvortrup, C, Nygård, S B, Nielsen, S L, Andersen, D R, Jensen, N F, Stenvang, J, Detlefsen, S, Brünner, N & Pfeiffer, P 2016, ' A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification ', BMC Cancer, vol. 16, 91 . https://doi.org/10.1186/s12885-016-2124-5
Tarpgaard, L S, Qvortrup, C, Nygård, S B, Nielsen, S L, Andersen, D R, Jensen, N F, Stenvang, J, Detlefsen, S, Brünner, N & Pfeiffer, P 2016, ' A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification ', B M C Cancer, vol. 16, 91 . https://doi.org/10.1186/s12885-016-2124-5
UNLABELLED: ᅟ: The overall purpose of this study is to provide proof of concept for introducing the anthracycline epirubicin as an effective, biomarker-guided treatment for metastatic colorectal cancer (mCRC) patients who are refractory to treatmen
Autor:
Nils Brünner, Anne-Sofie Schrohl, Yves Pommier, Petra Hamerlik, Magnus Stougaard, John A. Foekens, Birgitta R. Knudsen, Signe Lykke Nielsen, José M.A. Moreira, Marcel Smid, Kristina Aluzaite, Stine Ninel Hansen, John W.M. Martens, Madhavsai K. Gajjar, Julie B. Noer, Britt Damsgaard, Haatisha Jandu, Louise Fogh, Khoa Nguyen Do, Jan Stenvang, Joanna Proszek, Sebastian Wingaard Thrane
Publikováno v:
Jandu, H, Aluzaite, K, Fogh, L, Thrane, S W, Noer, J B, Proszek, J, Do, K N, Hansen, S N, Damsgaard, B, Nielsen, S L, Stougaard, M, Knudsen, B R, Moreira, J, Hamerlik, P, Gajjar, M, Smid, M, Martens, J, Foekens, J, Pommier, Y, Brünner, N, Schrohl, A-S & Stenvang, J 2016, ' Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines ', BMC Cancer, vol. 16, no. 1, 34 . https://doi.org/10.1186/s12885-016-2071-1
BMC Cancer
Jandu, H, Aluzaite, K, Fogh, L, Thrane, S W, Noer, J B, Proszek, J, Nguyen Do, K, Hansen, S N, Damsgaard, B, Nielsen, S L, Stougaard, M, Knudsen, B R, Moreira, J, Hamerlik, P, Gajjar, M, Smid, M, Martens, J, Foekens, J, Pommier, Y, Brunner, N, Schrohl, A-S & Stenvang, J 2016, ' Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines ', B M C Cancer, vol. 16, no. 1, 34 . https://doi.org/10.1186/s12885-016-2071-1
BMC Cancer, 16:34. BioMed Central Ltd.
BMC Cancer
Jandu, H, Aluzaite, K, Fogh, L, Thrane, S W, Noer, J B, Proszek, J, Nguyen Do, K, Hansen, S N, Damsgaard, B, Nielsen, S L, Stougaard, M, Knudsen, B R, Moreira, J, Hamerlik, P, Gajjar, M, Smid, M, Martens, J, Foekens, J, Pommier, Y, Brunner, N, Schrohl, A-S & Stenvang, J 2016, ' Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines ', B M C Cancer, vol. 16, no. 1, 34 . https://doi.org/10.1186/s12885-016-2071-1
BMC Cancer, 16:34. BioMed Central Ltd.
Background Studies in taxane and/or anthracycline refractory metastatic breast cancer (mBC) patients have shown approximately 30 % response rates to irinotecan. Hence, a significant number of patients will experience irinotecan-induced side effects w
Autor:
Nils Brünner, Ben Vainer, Ib Jarle Christensen, Maria Unni Rømer, Sven Müller, David Hersi Smith, Kirsten Vang Nielsen, Sune Boris Nygård, Hans Jørgen Nielsen, Signe Lykke Nielsen
Publikováno v:
Molecular Oncology. 7:101-111
Purpose A Topoisomerase 1 (Top1) poison is frequently included in the treatment regimens for metastatic colorectal cancer (mCRC). However, no predictive biomarkers for Top1 poisons are available. We here report a study on the TOP1 gene copy number in
Autor:
Nils Brünner, Signe Lykke Nielsen, Kirsten Vang Nielsen, Maria Unni Rømer, Niels Frank Jensen, Hans Jørgen Nielsen, Sven Müller
Publikováno v:
Scandinavian Journal of Gastroenterology. 47:68-79
A positive relationship between topoisomerase-1 (TOP1) protein and sensitivity toward the TOP1 inhibitor irinotecan has been reported in patients with metastatic colorectal cancer (mCRC). In this study, we analyzed TOP1 gene copy number variation in
Autor:
Signe Lykke Nielsen, Hans Christian Pedersen, Sussie Steen Jensen, Nils Brünner, Anne-Sofie Schrohl
Publikováno v:
Histopathology
Schrohl A-S, Pedersen H C, Jensen S S, Nielsen S L & Brunner N (2011) Histopathology59, 975–983 Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies Aims: The availability of specific